JP2014506913A5 - - Google Patents

Download PDF

Info

Publication number
JP2014506913A5
JP2014506913A5 JP2013555935A JP2013555935A JP2014506913A5 JP 2014506913 A5 JP2014506913 A5 JP 2014506913A5 JP 2013555935 A JP2013555935 A JP 2013555935A JP 2013555935 A JP2013555935 A JP 2013555935A JP 2014506913 A5 JP2014506913 A5 JP 2014506913A5
Authority
JP
Japan
Prior art keywords
deoxyuridine
fluoro
phosphate
naphthyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013555935A
Other languages
English (en)
Japanese (ja)
Other versions
JP5978232B2 (ja
JP2014506913A (ja
Filing date
Publication date
Priority claimed from GBGB1103582.1A external-priority patent/GB201103582D0/en
Priority claimed from GBGB1105660.3A external-priority patent/GB201105660D0/en
Application filed filed Critical
Priority claimed from PCT/GB2012/050457 external-priority patent/WO2012117246A1/en
Publication of JP2014506913A publication Critical patent/JP2014506913A/ja
Publication of JP2014506913A5 publication Critical patent/JP2014506913A5/ja
Application granted granted Critical
Publication of JP5978232B2 publication Critical patent/JP5978232B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013555935A 2011-03-01 2012-02-29 がん治療での使用のための5−フルオロ−2’−デオキシウリジンのホスホラミダート誘導体 Active JP5978232B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1103582.1A GB201103582D0 (cg-RX-API-DMAC7.html) 2011-03-01 2011-03-01
GB1103582.1 2011-03-01
GBGB1105660.3A GB201105660D0 (en) 2011-04-01 2011-04-01 Chemical compounds
GB1105660.3 2011-04-01
PCT/GB2012/050457 WO2012117246A1 (en) 2011-03-01 2012-02-29 Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2014506913A JP2014506913A (ja) 2014-03-20
JP2014506913A5 true JP2014506913A5 (cg-RX-API-DMAC7.html) 2015-04-16
JP5978232B2 JP5978232B2 (ja) 2016-08-24

Family

ID=45841523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013555935A Active JP5978232B2 (ja) 2011-03-01 2012-02-29 がん治療での使用のための5−フルオロ−2’−デオキシウリジンのホスホラミダート誘導体

Country Status (28)

Country Link
US (7) US8933053B2 (cg-RX-API-DMAC7.html)
EP (4) EP3447061B1 (cg-RX-API-DMAC7.html)
JP (1) JP5978232B2 (cg-RX-API-DMAC7.html)
KR (1) KR101885940B1 (cg-RX-API-DMAC7.html)
CN (2) CN103403013B (cg-RX-API-DMAC7.html)
AU (1) AU2012223012C1 (cg-RX-API-DMAC7.html)
BR (1) BR112013021986B1 (cg-RX-API-DMAC7.html)
CA (1) CA2828326C (cg-RX-API-DMAC7.html)
CL (1) CL2013002517A1 (cg-RX-API-DMAC7.html)
CY (2) CY1117445T1 (cg-RX-API-DMAC7.html)
DK (3) DK2681227T3 (cg-RX-API-DMAC7.html)
ES (4) ES2903097T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20160346T1 (cg-RX-API-DMAC7.html)
HU (2) HUE029022T2 (cg-RX-API-DMAC7.html)
IL (1) IL228169A (cg-RX-API-DMAC7.html)
LT (1) LT3447061T (cg-RX-API-DMAC7.html)
MX (1) MX339822B (cg-RX-API-DMAC7.html)
NZ (1) NZ615270A (cg-RX-API-DMAC7.html)
PH (2) PH12013501723A1 (cg-RX-API-DMAC7.html)
PL (3) PL3447061T3 (cg-RX-API-DMAC7.html)
PT (2) PT3447061T (cg-RX-API-DMAC7.html)
RS (2) RS54776B1 (cg-RX-API-DMAC7.html)
RU (1) RU2614406C2 (cg-RX-API-DMAC7.html)
SG (1) SG192841A1 (cg-RX-API-DMAC7.html)
SI (2) SI2681227T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202100715T1 (cg-RX-API-DMAC7.html)
WO (1) WO2012117246A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201306468B (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
EP3447061B1 (en) 2011-03-01 2021-11-24 NuCana plc Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
AU2013346515B2 (en) 2012-11-16 2017-05-25 NuCana plc Process for preparing nucleoside prodrugs
WO2015013352A2 (en) * 2013-07-25 2015-01-29 Patel Hasmukh B Nucleoside phosphoramidates and phosphoramidites
CN104447923B (zh) * 2013-09-23 2018-03-30 中国药科大学 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
RU2553996C1 (ru) * 2013-11-27 2015-06-20 Андрей Александрович Иващенко Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
JP2017516779A (ja) * 2014-05-28 2017-06-22 アイデニクス・ファーマシューティカルズ・エルエルシー 癌治療のためのヌクレオシド誘導体
CN105153257B (zh) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 索非布韦的制备方法
MY183198A (en) 2014-06-25 2021-02-18 Nucana Biomed Ltd Gemcitabine prodrugs
PL225283B1 (pl) * 2014-07-24 2017-03-31 Univ Im Adama Mickiewicza W Poznaniu Pochodne 2,3’-anhydro-2’-deoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób wytwarzania i zastosowanie
EA031727B1 (ru) 2014-11-28 2019-02-28 НУКАНА ПиЭлСи Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
KR102363946B1 (ko) 2015-03-06 2022-02-17 아테아 파마슈티컬즈, 인크. HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
CN108368147A (zh) * 2015-05-27 2018-08-03 南方研究院 用于治疗癌症的核苷酸
MX2018005872A (es) 2015-11-16 2019-05-16 Ichorion Therapeutics Inc Profarmacos de acido nucleico.
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
HRP20220278T1 (hr) 2016-09-07 2022-05-13 Atea Pharmaceuticals, Inc. 2'-supstituirani-n6-supstituirani purinski nukleotidi za liječenje bolesti izazvanih rnk virusima
CN110087666B (zh) 2016-11-13 2024-04-30 想象制药公司 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法
CN109863160B (zh) 2016-12-23 2022-06-07 四川科伦博泰生物医药股份有限公司 核苷磷酸类化合物及其制备方法和用途
RU2644156C1 (ru) * 2017-02-28 2018-02-08 Александр Васильевич Иващенко Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN111315446A (zh) 2017-08-08 2020-06-19 中山大学 用于治疗多药耐药性肿瘤的方法和组合物
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
GB201715011D0 (en) * 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
CN111836823B (zh) * 2018-03-09 2023-06-30 国立研究开发法人科学技术振兴机构 β修饰磷酸化合物前体、β修饰磷酸化合物、反应阻碍剂和包含这些化合物的医药品以及反应阻碍方法
CN110387226A (zh) * 2018-04-20 2019-10-29 天津大学 一种用于检测肿瘤的荧光探针及用途
US12221649B2 (en) * 2018-11-30 2025-02-11 The University Of Tokyo Fluorescent probe for detecting carboxypeptidase activity
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
CN110840907B (zh) * 2019-08-16 2022-11-25 南京医科大学 一类自由基敏感的尿嘧啶类ProTide前药及其药物用途
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
CN116368143A (zh) * 2020-08-31 2023-06-30 埃莫里大学 5'-取代的单磷酸核苷、其前药及其相关用途
EP4630433A1 (en) 2022-12-07 2025-10-15 NuCana plc Synthesis of nucleoside derivative nuc-3373

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US1002239A (en) 1902-04-11 1911-09-05 Stromberg Carlson Telephone Telephone system.
US2945038A (en) 1956-09-26 1960-07-12 Hoffmann La Roche 5-fluorocytosine and preparation thereof
US3201387A (en) 1963-09-18 1965-08-17 Heidelberger Charles 5-trifluoromethyluracil, derivatives thereof, and processes for preparing the same
US3792039A (en) 1971-12-27 1974-02-12 Miles Lab Poly 2'-fluoro-2'-deoxyuridylic acid
DD279248A1 (de) 1989-01-01 1990-05-30 Akad Wissenschaften Ddr Verfahren zur herstellung von 2',3'-didesoxythymidin-5'-diamidophosphaten
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
RU2197964C2 (ru) * 1995-04-12 2003-02-10 Дзе Проктер Энд Гэмбл Компани Фармацевтическая композиция, композиция стандартной лекарственной формы и способ лечения злокачественных новообразований, опухолей и вирусных инфекций
WO1999037753A1 (en) 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
CN1390227A (zh) 1999-07-22 2003-01-08 新生物生物公司 酶催化的治疗活化
DE10109657A1 (de) 2001-02-28 2002-09-05 Menarini Ricerche Spa Verfahren zur Herstellung von (E)-5-(2-Bromvinyl)-2`-desoxyuridin
WO2003000713A1 (en) 2001-06-21 2003-01-03 Glaxo Group Limited Nucleoside compounds in hcv
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
US8399428B2 (en) 2004-12-09 2013-03-19 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
JP2009504704A (ja) 2005-08-15 2009-02-05 エフ.ホフマン−ラ ロシュ アーゲー 抗ウイルス4′−置換プロヌクレオチドホスホルアミダート
WO2007056596A2 (en) 2005-11-09 2007-05-18 Wayne State University Phosphoramidate derivatives of fau
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
CN101922935B (zh) 2010-07-16 2012-07-18 北京大学 一种最小互易结构干涉型全光纤陀螺仪
EP2596004B1 (en) 2010-07-19 2014-09-10 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
CA2810928A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
WO2012048013A2 (en) 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
WO2012117027A1 (en) 2011-03-01 2012-09-07 Janssen Pharmaceutica Nv 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace)
EP3447061B1 (en) * 2011-03-01 2021-11-24 NuCana plc Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
NO3119794T3 (cg-RX-API-DMAC7.html) 2014-06-25 2018-03-10
EA031727B1 (ru) 2014-11-28 2019-02-28 НУКАНА ПиЭлСи Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
TR201806642T4 (tr) 2015-05-14 2018-06-21 NuCana plc Kanser tedavileri.
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Similar Documents

Publication Publication Date Title
JP2014506913A5 (cg-RX-API-DMAC7.html)
RU2013143862A (ru) Фосфороамидатные производные 5-фтор-2'-дезоксиуридина для применения для лечения рака
US12098139B2 (en) Chemokine receptor modulators and uses thereof
US10604526B2 (en) Chemokine receptor modulators and uses thereof
US10946033B2 (en) 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment
US10246462B2 (en) Chemokine receptor modulators and uses thereof
US10011629B2 (en) Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
JP2017036314A5 (cg-RX-API-DMAC7.html)
CN102395590A (zh) 用于治疗癌症和病毒感染的嘌呤核苷单磷酸酯前药
CN118834840A (zh) 嵌合痘病毒组合物及其用途
CN107108683A (zh) 用于治疗黄病毒科病毒和癌症的2’,2’‑二卤代核苷类似物
JP2014534269A5 (cg-RX-API-DMAC7.html)
CN114867351A (zh) 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途
JP2012522842A5 (cg-RX-API-DMAC7.html)
JP2014510699A5 (cg-RX-API-DMAC7.html)
CN109843329A (zh) 使用mdm2抑制剂和dna甲基转移酶抑制剂的组合治疗方法
JP2009527463A5 (cg-RX-API-DMAC7.html)
CN115461054A (zh) 延伸因子1-α抑制剂及其用途
CN102319247A (zh) 一种靶向于mir-26a的抗肿瘤小分子化合物
US20230114304A1 (en) Depalmitoylating compositions and the use thereof
CN101980713A (zh) 含有胞嘧啶核苷衍生物与卡铂的抗肿瘤剂